[Quantiferon-plus: the new tuberculosis assessment test]
Abstract
A main feature of Mycobacterium tuberculosis infection, even among subject without overt signs or symptoms of the disease (latent TB subjects), is the dynamic equilibrium between the host immune system and the bacilli, as highlighted by the heterogeneity and spectrum of conditions which we can only partially understand in humans. The many studies carried out in large cohorts of subjects infected with M. tuberculosis with IGRAs allowed a better understanding of the host immune response against the tubercle bacillus and comprehend the complexity of the host-bacilli interplay. The development of new GRAs, capable of distinguishing the immune responses elicited in infected subjects (active TB patients and latent TB subjects) and the possibility to correlate these immune responses with clinical conditions and outcomes may pave the way for a better understanding of the infectious process and identify immunological correlates of risk which may be instrumental for a better control of the disease.
References
- 1) Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. J Rheumatol 2014; Suppl 91: 11-16. doi:91/0/11 [pii];10.3899/jrheum. 140097 [doi]. DOI: https://doi.org/10.3899/jrheum.140097
- 2) Delogu G, Provvedi R, Sali M, Manganelli R. Mycobacterium tuberculosis virulence: insights and impact on vaccine development. Future Microbiol 2015; 10:1177-1194. doi: 10.2217/fmb. 15.26 [doi]. 3) Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol 2014; Suppl 91: 24-31. doi:91/0/24 [pii];10.3899/jrheum. 140099 |do1].
- 4) Delogu G, Chiacchio T, Vanini V, Butera O, Cuzzi G, Bua A, Molicotti P, Zanetti S, Lauria FN, Grisetti S, Magnavita N, Fadda G, Girardi E, Goletti D. Methylated HBHA produced in M. smegmatis Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. PLoS.ONE 2011; 6:e 1815. DOI: https://doi.org/10.1371/journal.pone.0018315
- 5) Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, Codecasa LR, Cugnata F, Di SC, Ferrarese M, Goletti D, Lipman M, Rancoita PM, Russo G, Tadolini M, Vanino E, Cirillo DM. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J 2016; doi: 13993003.00510-2016 [pii];10.1183/ 13993003.00510-2016 |do1].
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2016 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.